Munich Re logo
Not if, but how

Explore Munich Re Group

Get to know our Group companies, branches and subsidiaries worldwide.

Medical risk research
© Thomas Barwick / Getty Images

Medical risk research

We transform medical advances into insurance solutions

    alt txt

    properties.trackTitle

    properties.trackSubtitle

    Evidence-based decisions founded on the latest knowledge

    Global networked risk research
    © Scanderbeg Sauer Photography
    Globally networked
    Munich Re bundles its global expertise in the centre of competence for medical risk research.
    Medicine is advancing rapidly — bringing with  it  new opportunities and risks in life and health insurance. For instance, new diagnosis and treatment options are lowering morbidity and mortality rates in many diseases. Such developments must be factored into risk and claims assessments in order to avoid the risk of discrimination lawsuits and damage to a company's reputation. The insurance industry needs to monitor these developments closely and continually update its assessment principles and methods. This necessitates more in-depth medical and actuarial expertise than was previously required. Munich Re has both. We pool our global expertise in our centre of competence for medical risk research and provide primary insurers with direct access to our experts. In doing so, we are contributing towards a rapid expansion in insurability and are helping ensure that medical progress is reflected in evidence-based decisions.  

    The "Right to be forgotten" (RTBF): EU legislation and its potential impact on Life insurance

    Cancer – advances in medicine leading to extended insurability for cancer survivors

    The "Right to be forgotten" prohibits insurers from acquiring or using information from cancer survivors concerning their cancer after a certain period of time. Based on figures from the German market our experts have developed a calculation model to examine the potential impact of this legislation on the insurance industry.  To learn more about the current insights and assessments  download  the PDF.
    Over the past years medical advances in cancer treatment, prevention and screening have made significant steps, which has led to a steadily declining mortality. As a consequence, it is of utmost importance for us as Munich Re to monitor these developments and to reflect mortality improvements in our evidence-based underwriting manual.  To learn more about the current insights and assessments  download  the PDF.

    Our focal areas of medical risk research

    No. 1
    Mental diseases are the number 1 trigger for benefits in disability income insurance.

    Mental health conditions are now the number one cause of occupational disability claims. By way of example, around 30% of all disability claims in the German market relate to mental health conditions. Most claims cannot be assessed adequately  on the basis of  conventional questionnaires and standard processes. This frequently results in overhasty evaluations, in some cases with medical assessments being accepted without question. As mental health conditions often have a poor medical prognosis, a high number of patients experience  chronification  and recovery rates are low,  payouts  for such conditions frequently continue until the insurance policy expires.  

    "Psyche" claims initiative

    Munich Re has launched the "Psyche" claims initiative to tackle the challenges outlined above. This initiative aims to optimise the disability claims assessment process and ensure that appropriate decisions are reached. Working together with pilot partners from the primary insurance industry, we have developed innovative tools that enable precisely this. The result is an innovative workflow for the assessment of mental health claims. This new workflow delivers short reaction times, appropriate assessments  and also  cost savings.

    15 %
    Already today, up to 15 % of the cancer treatment costs for some health insurers are attributable to immunotherapies.

    Almost every day, new reports emerge relating to the successful use of immunotherapy. Many cancer patients are  already  benefiting from such treatment.  However, in others the resulting immune responses in the body cause  additional  complications. There  is  no doubt that the treatment  opens up  new prospects – both in medicine and in the insurance sector.

    New demand: a challenge and an opportunity for private health and life insurers

    Personalised immunotherapies are expensive, accounting for up to 15% of the cancer treatment costs of primary health insurers.  Any insurer that refuses to meet the cost of treatment citing the lack of long-term studies and of licensed drugs without studying the  matter closely is putting their own reputation at serious risk. On the other hand, cost pressures  on  state health insurance schemes are  growing, prompting new demand for insurance  in some countries.

    Challenges presented by expanded insurability

    More and more cancers are changing from terminal illnesses to chronic impairments. Munich Re has its finger on the pulse of this change. We are continually evaluating all available clinical studies from around the world and translating the latest findings into insurance solutions. This enables us to support you in continually expanding the insurability of cancer and positioning yourself on the market as an innovative health insurer.  

    10 %
    According to estimates from the Munich Re medical centre of competence, up to 10 % of the German population will be affected by rare diseases by 2020 .

    Anyone  applying for life insurance has the right to an individual and fair risk assessment. Yet what happens if the applicant  discloses  a condition that even the company's own medical officer has never heard of? The challenge  for risk assessors  is to demonstrably assess  the individual risk  based on statistical evidence and therefore in accordance with the law  in spite of  the meagre  data available. This ties up capacities and takes time.

    The Gate – globally networked specialist knowledge, faster processing times, maximum legal certainty

    Munich Re has developed the internal knowledge platform  Get Access  To  Medical Expertise, or "The Gate" for short,  to enable existing knowledge to be retrieved at any time and from anywhere in the world and to systematically increase productivity when assessing medical risk for rare diseases. Local medical consultants at Munich Re can  use  "The Gate" to obtain instant access to expertise and  existing  models for assessing individual medical  cases.

    45 %
    A Munich Re analysis performed on behalf of the disability insurance industry reveals that 45 % of all GP reports requested at a later date justify higher premiums.

    The health questions in the application process employed by life insurers represent another key area of research for the medical consultants at Munich Re. Their aim is to reduce the number of questions, and thereby the effort for all parties involved, without reducing the risk quality. Continual cost-benefit analyses of all processes involved in application and risk assessment play a key role in this. For instance, which questions reliably reveal important medical information, and which could be omitted?  

    Let's look at GP reports as an example. Requesting and evaluating these reports costs time and money. As a result, there is a risk that clients may withdraw their applications due to the delays associated with obtaining information from their GP. However, this perspective ignores the fact that the value of the information contained in the GP reports is significantly greater than the risk described above. Without these reports, details of medical conditions that are essential for drawing up policy agreements in line with the degree of risk would often remain unknown. GP reports are therefore instrumental in protecting insurers against unjustified claims.  

    5 %
    It has been proven: Only 5 % of overweight insured persons are responsible for 80 % of benefit claims.

    The example of obesity: The number of applicants with an increased BMI will continue to rise. For life insurers this means that in future only a fraction of the population will be insurable at normal prices based on conventional risk assessment. Insurers who refuse to take a softer approach to BMI thresholds at the expense of risk quality must be prepared to see a fall in new business or expand insurability using a more sophisticated risk assessment. It is for this exact purpose that Munich Re has developed the new Multi-Risk Calculator for the MIRA risk assessment tool.  

    The first of its kind, this new calculator evaluates an applicant's BMI, blood pressure, cholesterol and smoking status. The result? Many applicants with an increased BMI can be insured more cheaply than before if, for instance, their blood pressure and cholesterol values are within the normal range.

    3 reasons to choose Munich Re

    State-of-the-art medical risk decisions based on legal certainty
    Direct access to Munich Re's world-leading centre of competence for medical risk research and the latest findings
    Competetive advantages through continuous expansion of insurability